SEC Form 4 · accession 0001209191-18-047297
BIOLASE, INC · BIOL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John R Beaver
Officer — EVP & Chief Financial Officer
Period of report
Aug 15, 2018
Accepted (ET)
Aug 17, 2018 · 3:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000811240
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 15, 2018 | P | 6,077 | $1.58 | A | 6,077 | D | |
| Common StockF2 | Aug 16, 2018 | P | 18,923 | $1.70 | A | 25,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.60, inclusive. The reporting person undertakes to provide to Biolase, Inc., any security holder of Biolase, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.60 to $1.75, inclusive. The reporting person undertakes to provide to Biolase, Inc., any security holder of Biolase, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.